The molecular targets of approved treatments for pulmonary arterial hypertension

Until recently, three classes of medical therapy were available for the treatment of pulmonary arterial hypertension (PAH)—prostanoids, endothelin receptor antagonists and phosphodiesterase type 5 (PDE5) inhibitors. With the approval of the soluble guanylate cyclase stimulator riociguat, an addition...

Descripción completa

Detalles Bibliográficos
Autores principales: Humbert, Marc, Ghofrani, Hossein-Ardeschir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4717417/
https://www.ncbi.nlm.nih.gov/pubmed/26219978
http://dx.doi.org/10.1136/thoraxjnl-2015-207170

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4717417/
https://www.ncbi.nlm.nih.gov/pubmed/26219978
http://dx.doi.org/10.1136/thoraxjnl-2015-207170

Ejemplares similares